لخّصلي

Clinical interpretation:

?Evidence is not yet sufficient to conclude that resmetirom prevents cirrhosis, hepatic decompensation, transplantation, liver cancer, cardiovascular events, or mortality.Not a substitute for metabolic management: It is indicated with diet and exercise, while diabetes, obesity, hypertension, and dyslipidemia still require optimized management.Lipid benefit: The LDL-C reduction may be particularly advantageous because many patients with MASH have substantial cardiometabolic risk.No established hard-outcome benefit yet: Current approvals are based on surrogate histologic endpoints.MASH resolution: Absolute benefit was approximately 16-20 percentage points beyond placebo.Fibrosis regression: Absolute benefit was approximately 10-12 percentage points beyond placebo.????

Clinical interpretation:

● MASH resolution: Absolute benefit was approximately 16–20 percentage points beyond placebo.
● Fibrosis regression: Absolute benefit was approximately 10–12 percentage points beyond placebo.
● Lipid benefit: The LDL-C reduction may be particularly advantageous because many patients with MASH have substantial cardiometabolic risk.
● Not a substitute for metabolic management: It is indicated with diet and exercise, while diabetes, obesity, hypertension, and dyslipidemia still require optimized management.
● No established hard-outcome benefit yet: Current approvals are based on surrogate histologic endpoints. Evidence is not yet sufficient to conclude that resmetirom prevents cirrhosis, hepatic decompensation, transplantation, liver cancer, cardiovascular events, or mortality. Confirmatory long-term outcome data are still required.